BIOCON
BiotechnologyBiocon Ltd.
Biocon Limited is a leading biopharmaceutical company based in India. It was founded in 1978 by Kiran Mazumdar-Shaw, who currently serves as the Executive Chairperson of the company. Biocon's primary focus is on research, development, and manufacturing of high-quality, affordable biopharmaceuticals, including biosimilars, novel biologics, and complex APIs (Active Pharmaceutical Ingredients).
Over the years, Biocon has expanded its product portfolio and entered new therapeutic areas, including oncology, diabetes, and immunology. The company has also formed strategic partnerships with global pharmaceutical companies to drive growth and expand its international presence.
Biocon has been performing well and has been recognized as a leading player in the global biosimilars market.
Business model: Biocon operates through a vertically integrated business model, encompassing R&D, manufacturing, and commercialization of biopharmaceutical products. The company earns revenues through the sale of its products and licensing agreements with other pharmaceutical companies.
Target customer segment: Biocon's customers include pharmaceutical companies, healthcare providers, and patients across various therapeutic areas, such as diabetes, oncology, and immunology.
Geographies: Biocon primarily serves the Indian market but has also expanded its operations to more than 120 countries across the globe.
- Trades at a P/E of 41, with a return on equity (ROE) of 5.25%.
- BIOCON is trading above 4 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 12.72%, and up 6.25% over the past year.
- At ₹433.65 it sits about 88% of the way up its 52-week range (₹331.00–₹447.15).
- Offers a dividend yield of 0.15%.
- Market capitalisation stands at ₹52,095 Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹1,993 Cr | ₹2,848 Cr | ₹23.72 | 142.9% |
| Mar 2022 | ₹8,184 Cr | ₹648 Cr | ₹5.40 | 7.92% |
| Mar 2021 | ₹7,106 Cr | ₹740 Cr | ₹6.17 | 10.41% |
| Mar 2021 | ₹7,106 Cr | ₹740 Cr | ₹6.17 | 10.41% |
| Mar 2020 | ₹6,367 Cr | ₹748 Cr | ₹6.24 | 11.75% |
| Mar 2020 | ₹6,367 Cr | ₹748 Cr | ₹6.24 | 11.75% |
| Mar 2019 | ₹5,514 Cr | ₹905 Cr | ₹90.48 | 16.41% |
| Mar 2019 | ₹5,514 Cr | ₹905 Cr | ₹90.48 | 16.41% |
| Mar 2018 | ₹4,123 Cr | ₹372 Cr | ₹37.20 | 9.02% |
| Mar 2017 | ₹3,891 Cr | ₹612 Cr | ₹61.20 | 15.73% |
| Mar 2016 | ₹3,347 Cr | ₹550 Cr | ₹53.52 | 16.43% |
| Mar 2015 | ₹3,090 Cr | ₹497 Cr | ₹47.64 | 16.08% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| PANACEABIO PANACEA BIOTEC LTD. | 0 | ₹58.36 | -47.02% |
| ALPA ALPA LABORATORIES LTD. | 14.02 | ₹51.66 | 12.98% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 4,66,252 | ₹270.10 |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 4,66,252 | ₹270.10 |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 7,32,649 | ₹261.30 |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 7,32,649 | ₹261.30 |
| 11 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 5,37,316 | ₹277.40 |
| 11 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 5,37,316 | ₹277.40 |
| 19 Sept 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 3,65,477 | ₹291.25 |
| 19 Sept 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 3,65,477 | ₹291.25 |
| 01 Aug 2022 | ISHARES INDIA INDEX MAURITIUS COMPANY | SALE | 4,96,327 | ₹307.20 |
| 01 Aug 2022 | ISHARES MSCI INDIA ETF | PURCHASE | 4,96,327 | ₹307.20 |
| 18 Jul 2022 | ISHARES INDIA INDEX MAURITIUS COMPANY | SALE | 4,99,308 | ₹332.40 |
| 18 Jul 2022 | ISHARES MSCI INDIA ETF | PURCHASE | 4,99,308 | ₹332.40 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.